NCT00933517CompletedPhase 2
Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study
Centre Jean Perrin24 sites in 1 country62 target enrollmentStarted: September 1, 2009Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 62
- Locations
- 24
- Primary Endpoint
- To assess the rate of complete histological response, according to Chevallier's classification
Study Overview
Brief Summary
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ³ 18.- Performance status £ 2 (according to WHO criteria).
- •Patient has histologically confirmed, non-metastatic breast cancer, with a clinical tumour diameter of ³ 2 cm
- •HR negative and Her-2 negative.
- •Clinical stage II and IIIa.
- •Patients not previously treated by surgery, radiotherapy, hormone therapy or chemotherapy.· Haematology: o Neutrophil count ≥1.5x109/Lo Platelet count ≥100x109/Lo Leucocyte count > 3,000/mmo Hb> 9g/dl· Hepatic Function:o Total bilirubin ≤ 1.5 time the upper normal limit (UNL)o ASAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases ALAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL in presence of liver metastases Alkaline phosphatase ≤ 2.5 time the upper normal limit (UNL)· Renal Function· Creatinine clearance ≥50 mL/min and serum creatinine ≤1.5xUNL· Metabolic Function o Magnesium ≥ lower limit of normal. o Calcium ≥ lower limit of normal.
- •Patient with no progressive heart disease, and for whom anthracyclines are not contraindicated (normal FEV).
- •Patient has signed the consent forms for participation before inclusion in the trial.
- •Member of a Social Security scheme (or a beneficiary of such a scheme) according to the provisions of the law of 9 August 2004.
Exclusion Criteria
- •Male patients.
- •Her-2 positive patients
- •Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment.
- •Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment.
- •Any form of breast cancer other than those described in the inclusion criteria, particularly inflammatory and/or overlooked forms (T4b or T4d).
- •Non-measurable tumour.
- •Patients have already undergone surgery for their disease or have had primary axillary dissection.
- •Patient has already been treated for new breast cancer.
- •Patient is a ward.
- •Patient has a history of second cancer, with exception of in situ cervical cancer or basocellular skin cancer which is regarded as cured.
- •Patient has another disease which is deemed incompatible with the patient being included in the protocol.
- •Heart or kidney failure, medullary, respiratory or liver failure.
- •Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) £ 1 year before enrollment/randomization
- •History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
- •Significant neurological or psychiatric abnormalities.
- •Symptomatic or progressive disorder of the central nervous system (CNS) or metastasis at the initial check-up.
- •Peripheral neuropathy > grade 2 (NCI-CTCAE criteria, Version 3.0).
- •History of allergy to polysorbate
- •Concomitant treatment with a trial drug, participation in another clinical trial within < 30 days or previous chemotherapy.
- •Patient with no fixed address in the next 6 months or living at a distance from the treatment centre so it is difficult to check her progress.
- •Prior anti-EGFr antibody therapy (e.g.:cetuximab) or treatment with small molecule EGFr tyrosine kinase inhibitors (e.g.: erlotinib).
- •Known previous or ongoing abuse of narcotic drug, other medication or alcohol.
- •Any investigational agent within 30 days before initiation of study treatment. - Must not have had a major surgical procedure within 28 days of initiation of treatment.
- •Subject unwilling or unable to comply with study requirements.
Outcomes
Primary Outcomes
To assess the rate of complete histological response, according to Chevallier's classification
Time Frame: after 24 weeks of treatment
Secondary Outcomes
- the rate of complete histological response, according to Sataloff's classification; the rate of clinical, ultrasound, mammogram response, according to the WHO criteria; progression-free and overall survival; the tolerance.(After 24 weeks of treatment, at surgery and at five years)
Investigators
Study Sites (24)
Loading locations...
Similar Trials
Completed
Phase 2
Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.Breast CancerNCT00600249Centre Jean Perrin35
Completed
Phase 2
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IV Breast CancerLocally AdvancedBreast CancerNCT00378313NSABP Foundation Inc76
Unknown
Phase 3
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerInvasive Breast CancerNCT00486668NSABP Foundation Inc529
Completed
Phase 2
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast CancerHER2-negative Breast CancerNode-negative Breast CancerBreast CarcinomaBreast CancerNCT05150652Irada Ibrahim-zada8
Recruiting
Phase 1
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer PatientsHER2-positive Early Breast CancerNCT04750122Peking University People's Hospital46